文献速递前列腺癌

单侧高危前列腺癌患者机器人辅助根治性前列腺切除术中个体化神经保留算法的外部验证

External validation of an algorithm to personalize nerve sparing approaches during robot-assisted radical prostatectomy in men with unilateral high-risk prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-01-04

在264例单侧高危前列腺癌患者中验证预测对侧前列腺外延伸风险的现有算法,48例(18%)存在对侧前列腺外延伸,低、中、高危组对侧前列腺外延伸风险分别为8%、17.2%和30.8%,决策曲线分析再次证实该算法优于始终或从不保留神经的策略。

要点

  • 264例单侧高危前列腺癌患者中48例(18%)存在对侧前列腺外延伸。
  • 低、中、高危组对侧前列腺外延伸风险分别为8%、17.2%、30.8%。
  • 决策曲线分析证实该算法优于始终或从不保留神经的策略。

核心结论

  • 单侧高危前列腺癌男性中双侧切除可能并非总是合理,决策可基于所建议的列线图。

研究设计与样本

  • 对现有预测对侧前列腺外延伸风险算法的外部验证研究,纳入264例单侧高危前列腺癌患者。

主要发现

  • 264例患者中48例(18%)存在对侧前列腺外延伸。
  • 低、中、高危组对侧前列腺外延伸风险分别为8%、17.2%和30.8%。

关键数值与推荐

  • 低、中、高危组对侧前列腺外延伸风险分别为8%、17.2%和30.8%。

临床怎么用

  • 作者认为单侧高危前列腺癌男性中双侧切除可能并非总是合理,决策可基于所建议的列线图。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Limited evidence exists about preserving neurovascular bundles during radical prostatectomy (RP) for high-risk prostate cancer (HRPCa) patients. Hence, we validated an existing algorithm predicting contralateral extraprostatic extension (cEPE) risk in unilateral high-risk cases. This algorithm aims to assist in determining the suitability of unilateral nerve-sparing RP. Among 264 patients, 48 (18%) had cEPE. The risk of cECE varied: 8%, 17.2%, and 30.8% for the low, intermediate, and high-risk groups, respectively. Despite a higher risk of cECE among individuals classified as low-risk in the development group compared to the validation group, our algorithm's superiority over always/never nerve-sparing RP was reaffirmed by decision curve analysis. Therefore, we conclude that bilateral excision may not always be justified in men with unilateral HRPCa. Instead, decisions can be based on our suggested nomogram.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Sanchez L, Martini A, Zhuang J, et al. External validation of an algorithm to personalize nerve sparing approaches during robot-assisted radical prostatectomy in men with unilateral high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38177256. doi:10.1038/s41391-023-00779-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。